Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Stresses Stability In Settling Oklahoma Opioids Case

Executive Summary

Teva says paying $85m to settle claims it contributed to opioid abuse in Oklahoma is important in maintaining the stability of the heavily indebted group.

You may also be interested in...



Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases

Teva's business appears to be stabilizing but the company needs to resolve outstanding opioid liability litigation. CEO Schultz said he is hopeful a national  settlement framework will be finalized.

Teva's Opioid Options Come Into More Focus Ahead Of Third Quarter Financials

Investors may have more clarity on Teva's long-term outlook if the generic drug maker reaches a settlement in a big opioid case before it goes to trial in Ohio next week.

Opioid Litigation Clouds Loom Over Teva's Turnaround

Increasing uncertainty over Teva's liability in opioid litigation is weighing on the generic drug manufacturer, even as the North American generics business stabilized in the second quarter.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB140361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel